Enhance Portfolio & BroadenTherapeutic Focus

• rHemoglobin: Initiated Phase I clinicals

2001 Key R&D Achievements

• BPI/Neuprex: Initiated Phase II studies (with Xoma)

• Next Gen IGIV: Filed IND with FDA

• NeisVac-C (Mening C): Licensed in Europe, Canada, and Argentina

• Alpha-1-Antitrypsin: Completed Pre-clinical studies

• TBE Vaccine: Initiated Phase II/III studies in Germany

• Frozen Tisseel: Filed in Japan

• Hemofil M DVI: Completed production of pre-clinical lots

• rAHF-PFM: Complete adult enrollment Phase III (Global)

• Protein C (Ceprotin): European approval and launch

Previous slide

Next slide

Back to first slide

View graphic version